An inter-ministerial committee under the chairmanship ofCentral Drugs Standard Control Organisation(CDSCO) Joint Drug Controller S Eswara Reddy has been constituted to monitor trends of export and import of APIs (active pharmaceutical ingredients), formulations and medical devices to ensure their timely availability in the country and to prevent shortages,he added.
The committee submits its reports from time to time, Gowda said.
Availability of drugs has been ensured by coordinating with state health authorities like state drug controllers (SDCs) and central government authorities including CDSCO and the Directorate General of Health Services (DGHS), he said while detailing about the government's "timely and effective measures" in this regard.
The National Pharmaceutical Pricing Authority (NPPA) under the DoP collected the critical information from drug manufacturers that was used in decision making to ensure drug availability, Gowda said.
About the other measures, he said that "steps have been taken to ensure the availability of Heparin used in COVID-19 treatment. Further, on intervention in the issue of price-parity of N-95 masks by the NPPA, major manufacturers, importers of N-95 Masks have reduced their prices significantly up to 67 per cent".
The DoP also coordinated on issues related to production of raw material, medicines, medical devices, packaging material etc, he said.
It also ensured seamless movement of raw materials, packing materials, finished goods, manpower among other things to see availability of life saving essential drugs during the lockdown, Gowda said.
"The NPPA has taken various steps to ensure the availability of life saving essential drugs such as hydroxychloroquine, paracetamol, vaccines, anti-tuberculosis drugs, anti-diabetic drugs, cardiac drugs, imported anti-epileptic drugs and various COVID-19 drugs," the minister explained.
Further, on the intervention of the DoP, manufacturers of Remdesivir have created a helpline to make the drug available, Gowda said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.